Li Hui, vice chairman of the platform, and his party went to Beijing to visit Professor Guo Zikuan, a researcher and doctor of medicine of China Academy of Military Medical Sciences.
On the morning of January 17th, a delegation led by Li Hui, Vice Chairman of the platform, visited Professor Guo Zikuan, a researcher and MD at the Chinese Academy of Military Medical Sciences in Beijing, to exchange views and consult on the development prospects of the cell therapy field in the biopharmaceutical industry.
Li Hui stated that as a third-party platform for government industry investment promotion, the platform, while operating its own industry effectively, also shoulders the mission of providing industry consultation and attracting high-quality projects for the government. Henan Province, located in the Central Plains, has a large population and natural resource and market advantages for developing the biopharmaceutical industry, but its current development status is not satisfactory. This visit to Professor Guo aimed to provide professional guidance and answer their questions.
Professor Guo, drawing on his many years of experience, provided a detailed analysis of the current market situation in the biopharmaceutical industry, particularly in the cell therapy field, and offered constructive suggestions on current policy development directions and scientific research results. Professor Guo stated that the development of the biopharmaceutical industry should adhere to three principles: first, compliance with scientific principles; second, individual cases do not represent the entire population; and third, statistical principles. In the current complex market environment, it is necessary to combine one's own actual situation, promptly adjust thinking, and choose industry sectors suitable for current development. Professor Guo also recommended some high-quality projects based on Henan's resource advantages.
Professor Guo Zikuan is the Executive Deputy Editor-in-Chief of the *Chinese Journal of Experimental Hematology*, the Executive Editor-in-Chief of the *Chinese Journal of Tissue Engineering*, and an editorial board member of the *World Journal of Stem Cells*, *Chinese Journal of Cell Stem Cells*, and *Journal of Tissue Engineering and Reconstructive Surgery*. He graduated from the Department of Internal Medicine and Hematology at Peking University School of Medicine and has been engaged in basic and clinical research on cell therapy in recent years. He has led three National "863" projects and three National Natural Science Foundation of China projects, and participated in numerous national-level projects. In collaboration with several hospitals, he has conducted clinical trials on NK cell therapy for acute myeloid leukemia, mesenchymal stem cell therapy for graft-versus-host disease, immunotherapy for tumors, autologous stem cell therapy for femoral head necrosis, and epidermal cell transplantation for vitiligo. He has published over 30 international papers as corresponding author or first author and holds 11 national invention patents. He is skilled in the design and implementation of clinical trials for cell therapy and has unique insights into immunotherapy for leukemia, aplastic anemia, and solid tumors, as well as cell transplantation for refractory orthopedic and skin diseases.
.png)
